RNAseq correlative biomarkers IFIT1B and VSTM5 predict progression free survival and clinical benefit in a multi-site Phase I/II trial of Olaparib and Tremelimumab for gBRCAm recurrent ovarian cancer (LBA 11)
Autor: | Sarah Adams, Carolyn Muller, David O’Malley, Kari Ring, Robert Wenham, Karen Finkelstein, Teresa Rutledge, Elizabeth Lokich, Xavier Paliard, Olivier Rixe, Ichiko Kinjyo, Steven Eberhardt, Ji-Hyun Lee, Phyllis Gimotty |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Gynecologic Oncology. 166:S60-S61 |
ISSN: | 0090-8258 |
Databáze: | OpenAIRE |
Externí odkaz: |